A.R.T. Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

A.R.T. Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,125	Closed	-$503K	–	1088
2019 Q4	$503K	Buy	+1,125	New	+$399K	0.02%	854
2019 Q2	–	Sell	-388	Closed	-$163K	–	1699
2019 Q1	$163K	Buy	+388	New	+$156K	0.01%	1107
2017 Q3	–	Sell	-478	Closed	-$113K	–	1744
2017 Q2	$113K	Buy	+478	New	+$109K	0.01%	1241
2016 Q1	–	Sell	-65	Closed	-$42K	–	1710
2015 Q4	$42K	Buy	+65	New	+$36.8K	﹤0.01%	1389
2015 Q1	–	Sell	-25	Closed	-$223K	–	1748
2014 Q4	$223K	Buy	+25	New	+$145K	0.01%	1198

Other funds holding EIGR

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

A.R.T. Advisors's EIGR Position: Q1 2020 in Review

A.R.T. Advisors sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2020, closing a stake of 1,125 shares — an estimated $503K sold.

A.R.T. Advisors first reported a position in EIGR in Q4 2014 and held it in 5 quarters. The position peaked at $503K in Q4 2019. 93 funds tracked by Wall St. Rank hold EIGR as of Q1 2020.

A.R.T. Advisors reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
A.R.T. Advisors sold 1,125 Eiger BioPharmaceuticals, Inc. shares in Q1 2020, an estimated $503K.
A.R.T. Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2014 and held it in 5 quarters.
A.R.T. Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $503K in Q4 2019.
93 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.